Most Read Articles
16 May 2019
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Pearl Toh, 17 May 2019
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
Jairia Dela Cruz, 5 days ago
One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.
16 May 2019
Due to the increasing global prevalence of obesity, older adults may live more years of their remaining life with limited physical function and activities in daily living (ADLs), according to a study, adding that older adults, their families and healthcare systems should be aware of this problem.

Add-on fish oil lowers lipid levels in rosuvastatin-treated patients

26 Dec 2017

Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.

The trial randomized 201 patients (mean age 58.1 years; 62.7 percent male) to receive rosuvastatin 20 mg/d plus ω-3 fatty acids 4 g/d (ROSUMEGA group) or rosuvastatin 20 mg/d (rosuvastatin group) alone for 8 weeks. All patients had residual hypertriglyceridemia following a 4-week run-in period of rosuvastatin treatment.

Compared with those in the rosuvastatin group, patients in the ROSUMEGA group showed a significantly greater percentage change from baseline in triglycerides (–26.3 vs –11.4 percent; p<0.001) and non-HDL cholesterol (–10.7 vs –2.2 percent; p=0.001) following 8 weeks of treatment.

Linear regression analysis found that the lipid-lowering effect of omega-3 fatty acids was more pronounced when baseline triglycerides or non-HDL cholesterol levels were high and body mass index was low.

In terms of safety, the incidence of adverse events did not significantly differ between the two treatment groups.

Researchers pointed out that additional work must be conducted to determine whether the lipid-lowering effect of omega-3 fatty acids actually leads to the prevention of cardiovascular event.

Omega-3 fatty acids are derived from fatty fish and other seafood, and their consumption has been previously reported to decrease plasma triglycerides, resting heart rate, and blood pressure, as well as also improve myocardial filling and efficiency, lower inflammation, and improve vascular function. Omega-3 fatty acids affect multiple molecular pathways, including alteration of physical and chemical properties of cellular membranes, direct interaction with and modulation of membrane channels and proteins, regulation of gene expression via nuclear receptors and transcription factors, changes in eicosanoid profiles, and conversion of n-3 PUFA to bioactive metabolites. [J Am Coll Cardiol 2011;58:2047–2067]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
16 May 2019
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Pearl Toh, 17 May 2019
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
Jairia Dela Cruz, 5 days ago
One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.
16 May 2019
Due to the increasing global prevalence of obesity, older adults may live more years of their remaining life with limited physical function and activities in daily living (ADLs), according to a study, adding that older adults, their families and healthcare systems should be aware of this problem.